Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947412 | 0.89 | F9 (0.33) | MAPK14MEN1KMT2ARXFP1TRPV1 | |
| SCHEMBL1950694 | 0.85 | F9 (0.35) | TRPV1 | |
| Ammonia Solution, Strong SCHEMBL1949006 | 0.81 | F9 (0.46) | MAPK14MEN1KMT2ARXFP1TP53 | |
| SCHEMBL1946989 | 0.80 | F9 (0.36) | MAPK14HTR1ASLC6A2SLC6A3MEN1 | |
| SCHEMBL15103450 | 0.78 | F9 (0.37) | MAPK14MEN1KMT2ARXFP1TP53 | |
| Ammonia Solution, Strong SCHEMBL1445030 | 0.71 | F9 (0.48) | MAPK14MEN1KMT2ARXFP1TRPV1 | |
| SCHEMBL1947802 | 0.70 | F9 (0.39) | MAPK14MEN1KMT2ARXFP1TRPV1 | |
| SCHEMBL1947452 | 0.70 | SLC6A2 (0.35) | MAPK14HTR1ASLC6A2SLC6A3MEN1 | |
| SCHEMBL15103680 | 0.69 | F9 (0.39) | MAPK14TRPV1 | |
| Ammonia Solution, Strong SCHEMBL1950693 | 0.66 | F9 (0.51) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MAPK14 2257/4885HTR1A 4306/4885SLC6A2 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.